Market Newsdesk

PHILADELPHIA , July 26, 2023 (GLOBE NEWSWIRE) — Enviri Corporation (NYSE: NVRI) announced today that its Harsco Environmental division, a global leader in steel mill services and products, has successfully renewed the steel mill services and products agreement with ArcelorMittal Long Products at its Quebec, Canada site.

Under the two-year renewed agreement, Harsco Environmental will continue to offer a comprehensive range of essential services, including slag pit digging, metallic recovery, melt shop cleaning, support services, and ad-hoc rentals. These services are critical for maintaining smooth operations and optimizing productivity in the steel manufacturing process.

“We are delighted to continue our partnership with ArcelorMittal,” stated Mauro Curi, Vice President Global Mill Services, Harsco Environmental. “Our unwavering commitment to delivering sustainable solutions that enhance efficiency remains steadfast, and we are thrilled to extend our collaboration with this trusted partner.”

Harsco Environmental’s successful contract renewal with ArcelorMittal Long Products site further strengthen the company’s foothold as a leader in the industry. With a continued focus on delivering innovative and sustainable solutions, Harsco Environmental remains dedicated to supporting the growth and success of its valued partners.

About Harsco Environmental

Harsco’s Environmental division is the largest and most comprehensive provider of onsite material processing and environmental services to the global metals industry, with operations at over 130 customer sites across more than 32 countries. The division is a technology partner to cleaner, more efficient metal production, providing customers with economically and environmentally viable solutions for the treatment and reuse of production by-products. Visit harsco-environmental.com to learn more.

About
Enviri

Enviri is transforming the world to green as a trusted global leader in providing a broad range of environmental services and related innovative solutions. The Company serves a diverse customer base by offering critical recycle and reuse solutions for their waste streams, enabling customers to address their most complex environmental challenges and to achieve their sustainability goals. Enviri is based in Philadelphia, Pennsylvania, and operates in more than 150 locations in over 30 countries. Additional information can be found at www.enviri.com.

ASRS presentations will feature data from ZETA-1 Phase 2 trial evaluating APX3330 in diabetic retinopathy

End-of-Phase 2 meeting with FDA for APX3330 scheduled for Q4 2023

FARMINGTON HILLS, Mich., July 26, 2023 (GLOBE NEWSWIRE) — Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced that results from the ZETA-1 Phase 2 trial evaluating APX3330 in diabetic retinopathy will be presented at the American Society of Retinal Specialists (ASRS) annual scientific meeting to take place in Seattle, Washington, July 28 to August 1. In addition, Ronil Patel, MTech, MS, SVP of Operations & Business Development at Ocuphire, will provide a corporate update at the OIS Retina Innovation Summit on July 27, also in Seattle, Washington.

Ocuphire also announced that it has scheduled an End-of-Phase 2 meeting with the FDA in Q4 2023 to discuss the specifics of the APX3330 development program. In the ZETA-1 trial, APX3330 achieved statistical significance in preventing clinically meaningful progression of diabetic retinopathy (DR), as measured by the percentage of subjects with binocular ≥3-step worsening in DRSS, the anticipated Phase 3 primary endpoint. 

“APX3330 is the most advanced oral program currently in development for diabetic retinopathy, and the End-of-Phase 2 meeting confirmed for Q4 2023 is a critical milestone for our development program,” said Rick Rodgers, Interim Chief Executive Officer of Ocuphire. “Currently, patients with non-proliferative diabetic retinopathy (NPDR) are not treated due to the lack of non-invasive options on the market and the monthly time burden required for intravitreal injections. Eighty percent of physicians prefer to use a wait-and-see approach for these patients rather than delivering a monthly biologic treatment where patients often become incomplete responders. If approved, APX3330 has the potential to shift the treatment paradigm and be the first non-invasive, oral, early treatment for the 8 million NPDR patients who are at risk of progressing to vision-threatening complications. We look forward to working with the FDA to confirm the Phase 3 study design and advancing APX3330 towards a potential NDA submission.”

About Ocuphire Pharma

Ocuphire is a publicly traded (Nasdaq: OCUP), clinical-stage, ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders.

Ocuphire’s lead late-stage product candidate, APX3330, is a first-in-class, small molecule oral drug that blocks downstream pathways regulated by transcription factor Ref-1 – including those involving angiogenesis (VEGF) and inflammation (NFkB). These pathways are implicated in several ocular diseases, including diabetic retinopathy (DR), diabetic macular edema (DME), and age-related macular degeneration (AMD). Ocuphire recently announced topline data from the ZETA-1 Phase 2 trial in which APX3330 achieved statistical significance on a key pre-specified secondary endpoint of preventing clinically meaningful progression of DR after 24 weeks of daily treatment. APX3330 has also shown a favorable safety and tolerability profile in diabetic subjects (ZETA-1 trial) and in 11 previous clinical trials conducted in healthy, liver disease, and cancer subjects. An End-of-Phase 2 meeting with the FDA is confirmed for APX3330 in Q4 2023.

Ocuphire has a partnership with Viatris, Inc. to develop and commercialize Nyxol^® eye drops as a preservative-free eye drop formulation of phentolamine mesylate, a non-selective alpha-1 and alpha-2 adrenergic antagonist designed to reduce pupil size by uniquely blocking the alpha-1 receptors found only on the iris dilator muscle without affecting the ciliary muscle. Nyxol has been studied in a total of 12 clinical trials across three indications, including single-use for reversal of pharmacologically-induced mydriasis (RM), and once-daily for treatment of presbyopia and dim light (night) vision disturbances (DLD), pending regulatory approvals. Nyxol’s NDA under the 505(b)(2) pathway for the first indication, RM, has been accepted with a PDUFA date assigned of September 28, 2023. Nyxol is currently in Phase 3 for presbyopia and DLD.

For more information, visit www.ocuphire.com.

Forward Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements concerning the End-of-Phase 2 meeting with the FDA to confirm Phase 3 registration endpoints and study parameters, and the potential receipt of regulatory approval for Nyxol for the treatment of RM. These forward-looking statements are based upon Ocuphire’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including, without limitation: (i) the success and timing of regulatory submissions and pre-clinical and clinical trials, including enrollment and data readouts; (ii) regulatory requirements or developments; (iii) changes to clinical trial designs and regulatory pathways; (iv) changes in capital resource requirements; (v) risks related to the inability of Ocuphire to obtain sufficient additional capital to continue to advance its product candidates and its preclinical programs; (vi) legislative, regulatory, political and economic developments, (vii) changes in market opportunities, (viii) the effects of COVID-19 on clinical programs and business operations, (ix) risks that the Nyxol partnership may not facilitate the commercialization or market acceptance of Ocuphire’s product candidates; (x) the success and timing of commercialization of any of Ocuphire’s product candidates and (xi) the maintenance of Ocuphire’s intellectual property rights. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors detailed in documents that have been and may be filed by Ocuphire from time to time with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Ocuphire undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. 

Contacts

ZUG, Switzerland, and BOSTON, July 26, 2023 (GLOBE NEWSWIRE) — Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced that it will participate at the following upcoming investor conferences:

BTIG Virtual Biotechnology Conference 2023

Format: One-on-one meetings
Date: August 7 – 8, 2023
Location: Virtual

Wedbush PacGrow Healthcare Conference

Format: One-on-one meetings
Date and time: August 8 – 9, 2023
Location: New York, New York

H.C. Wainwright 3

^rd

Annual Ophthalmology Virtual Conference

Format: Company presentation
Date and time: Available on-demand Wednesday, August 16, 2023 at 7:00am ET
Location: Virtual
Webcast Link: https://journey.ct.events/view/1f5fe5a8-e1b8-43f9-9fb5-0775acd23032

The Oculis management team will be available for one-on-one meetings during the conferences. Interested investors should contact their respective representative at the sponsoring institutions to request meetings. Links to access company presentation for select events, when available, will be posted to Oculis’s website on the Events & Presentations page of the Investors section.

About Oculis

Oculis (Nasdaq: OCS) is a global biopharmaceutical company purposefully driven to save sight and improve eye care. Oculis’s highly differentiated clinical-stage pipeline comprises multiple innovative product candidates in development for eye diseases of high unmet need. It includes OCS-01 eye drops, a topical candidate in Phase 3 development for diabetic macular edema (DME) and inflammation and pain following ocular surgery; OCS-02 eye drops, a topical biologic candidate in Phase 2 development for dry eye disease (DED) and uveitis; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophthalmic disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The first in-patient, proof-of-concept trial with OCS-05 is currently ongoing in France. Headquartered in Switzerland and with operations in the US, Oculis’s goal is to deliver life-changing eye treatments to patients worldwide. The company is led by an experienced management team with a successful track record in the pharmaceutical industry, supported by leading international healthcare investors.

For more information, please visit: www.oculis.com

Oculis Contacts

Mrs. Sylvia Cheung, CFO
[email protected]

Investor & Media Relations

LifeSci Advisors
Corey Davis, Ph.D.
[email protected]
1-212-915-2577

CHICAGO, July 26, 2023 (GLOBE NEWSWIRE) — Whole Earth Brands, Inc. (the “Company”) (Nasdaq: FREE), a global food company enabling healthier lifestyles through premium plant-based sweeteners, flavor enhancers and other foods, today announced it will release its financial results for the second quarter ended June 30, 2023 before the market opens on Wednesday, August 9, 2023. The Company will host a conference call and webcast to discuss second quarter 2023 financial results at 8:30 am Eastern Time on the same day hosted by its executive management team.

Conference Call Details

The conference call can be accessed live over the phone by dialing (877) 704-4453 or for international callers by dialing (201) 389-0920. A replay of the call will be available until August 23, 2023 by dialing (844) 512-2921 or for international callers by dialing (412) 317-6671; the passcode is 13740110.

The live audio webcast of the conference call will be accessible in the News & Events section on the Company’s Investor Relations website at investor.wholeearthbrands.com. An archived replay of the webcast will also be available shortly after the live event has concluded.

About Whole Earth Brands

Whole Earth Brands is a global food company enabling healthier lifestyles and providing access to high quality plant-based sweeteners, flavor enhancers and other foods through our diverse portfolio of trusted brands and delicious products, including Whole Earth^®, Pure Via^®, Wholesome^®, Swerve^®, Canderel^® and Equal^®. With food playing a central role in people’s health and wellness, Whole Earth Brands’ innovative product pipeline addresses the growing consumer demand for more dietary options, baking ingredients and taste profiles. Our world-class global distribution network is the largest provider of plant-based sweeteners in more than 100 countries with a vision to expand our portfolio to responsibly meet local preferences. We are committed to helping people enjoy life’s everyday moments and the celebrations that bring us together. For more information on how we “Open a World of Goodness^®,” please visit www.WholeEarthBrands.com.

Contacts:

Investor Relations Contacts:
Whole Earth Brands
312-840-5001
[email protected]

ICR
Jeff Sonnek
646-277-1263
[email protected]